Advanced Immunotherapy at Istanbul Florence Nightingale HospitalCAR T-cell therapy is one of today’s most significant advances in oncology, offering new hope for patients with certain hard-to-treat blood cancers. Unlike traditional chemotherapy or radiation, this therapy uses a patient’s own immune cells—genetically re-engineered in the laboratory—to recognize and destroy cancer with remarkable precision. In this innovative …
CAR T-Cell Therapy: A Breakthrough in Personalized Cancer Treatment
Advanced Immunotherapy at Istanbul Florence Nightingale Hospital
CAR T-cell therapy is one of today’s most significant advances in oncology, offering new hope for patients with certain hard-to-treat blood cancers. Unlike traditional chemotherapy or radiation, this therapy uses a patient’s own immune cells—genetically re-engineered in the laboratory—to recognize and destroy cancer with remarkable precision. In this innovative process, a patient’s T-cells are collected and modified in the laboratory to carry specialized receptors known as chimeric antigen receptors (CARs).
This guide explains how CAR T-cell therapy works, which cancers it treats, what patients can expect, and how Istanbul Florence Nightingale Hospital delivers this advanced therapy with world-class expertise and patient-centered care.
What Is CAR T-Cell Therapy?
CAR T-cell therapy is a form of personalized immunotherapy that harnesses the body’s own immune system to fight cancer. T-cells collected from the patient are engineered to express chimeric antigen receptors (CARs)—synthetic receptors that enable the immune system to identify cancer cells that would otherwise remain undetected.
Once infused back into the patient, these “trained” immune cells act as living drugs:
- seeking out cancer cells,
- binding to them through specific antigens, and
- triggering a strong immune response that destroys the tumor.
This approach is both highly targeted and tailored to the individual, representing a new era of cellular and gene-modified cancer therapy.
How CAR T-Cell Therapy Works: Step by Step
1. T-Cell Collection (Leukapheresis)
A procedure similar to blood donation separates T-cells from the bloodstream by apheresis. The patient’s blood is processed through a machine that separates out white blood cells while the rest of the blood returns to the body. It usually takes 2–4 hours.
2. Genetic Engineering of T-Cells
In a specialized GMP laboratory, scientists introduce a gene encoding the Chimeric Antigen Receptors (CAR). This modification enables T-cells to recognize specific markers found on cancer cells. A lentiviral vector is being used for this.
The ongoing progress in T-cell engineering is making CAR T-cell therapy more powerful and safer, offering new hope for patients with challenging cancers.
3. Cell Expansion
After the T-cells are engineered, they undergo laboratory expansion. The engineered T-cells multiply into hundreds of millions of cells—enough to mount a strong therapeutic effect.
4. Lymphodepletion Chemotherapy
A short chemotherapy course prepares the body by creating space for the CAR T-cells to expand and function effectively. It helps the therapy work more efficiently by preparing the patient’s body to accept the new immune cells.
5. CAR T-Cell Infusion
The modified cells are infused back into the body through an IV line. This is typically done in a controlled hospital setting.
6. Intensive Monitoring
Patients remain closely observed for side effects, such as cytokine release syndrome or neurological symptoms —especially in the first 1–2 weeks. Our teams monitor vital signs, neurological status, and recovery markers to ensure safety at every step. In this context our CAR-T cell therapy is involved with the least side effects.
The full manufacturing and treatment process typically takes 3–5 weeks.
Which Cancers Can CAR T-Cell Therapy Treat?
FDA-approved CAR T-cell therapies currently target several types of blood cancers, especially when the disease is relapsed or refractory:
Acute Lymphoblastic Leukemia (ALL)
- Approved in children, young adults, and in select adult cases.
- Often achieves deep remission where multiple therapies may no longer be effective, offering the potential for long-term disease control and improved quality of life.
Lymphomas
CAR T-cell therapy is approved for several aggressive and treatment-resistant lymphomas:
- Diffuse Large B-Cell Lymphoma (DLBCL)
- Primary mediastinal B-cell lymphoma
- High-grade B-cell lymphoma
- Follicular lymphoma
- Mantle cell lymphoma
Multiple Myeloma
A major milestone, CAR T-cell therapy now offers new options for patients with relapsed or refractory myeloma after standard treatments.
Ongoing Research
Researchers worldwide are investigating CAR T-cell therapy for:
- solid tumors,
- additional leukemias,
- and earlier-line treatment in blood cancers.
Florence Nightingale International Hospital remains committed to pioneering the latest developments in CAR T-cell therapy and ensuring our patients have access to the most effective, cutting-edge treatments available. The field continues to evolve rapidly, providing renewed hope for patients and families facing cancer worldwide.
Potential Side Effects: What Patients Should Know
CAR T-cell therapy can cause strong immune activation. Most complications are manageable with prompt care, and Florence Nightingale’s expert hematology team follows internationally accepted guidelines for safe monitoring and treatment.
1. Cytokine Release Syndrome (CRS)
A systemic inflammatory response that may cause:
- fever or chills,
- fatigue,
- low blood pressure,
- difficulty breathing.
2. Immune Effector Cell–Associated Neurotoxicity Syndrome (ICANS)
Possible symptoms include:
- confusion or difficulty speaking,
- tremors,
- severe headache,
- seizures (rare).
3. Infections and Prolonged Cytopenias
Patients may develop:
- low neutrophils, red cells, or platelets,
- increased infection risk,
- temporary hypogammaglobulinemia.
Our multidisciplinary team—including hematologists, intensivists, neurologists, and immunologists—is specially trained to identify and manage these side effects quickly and effectively. With this expertise, most of these complications are reliably managed, ensuring patients have the best possible support during their therapy journey.
Future Directions in CAR T-Cell Therapy
Research continues to refine the safety and reach of CAR T-cell therapy:
- Next-generation CARs with enhanced signaling and lower toxicity
- Safety-switch CARs that can be controlled or deactivated
- Off-the-shelf (allogeneic) CAR T-cells that may reduce wait times
- Dual-targeting CARs to prevent antigen escape
- TIL therapy and other cellular immunotherapies for solid tumors
- Tumor-Infiltrating Lymphocytes (TIL) therapy is emerging as a related concept. TILs are immune cells naturally present within a tumor. These cells are collected from the patient, multiplied in the lab, and then reintroduced in large numbers. TIL therapy offers a personalized immune response, which can be especially effective for some solid tumors.
These innovations will shape the future of precision oncology and broaden access to transformative treatments.
CAR T-Cell Therapy at Istanbul Florence Nightingale Hospital
Florence Nightingale International Hospital is one of the region’s leading centers for advanced cellular therapies. Our program offers:
- FDA-approved CAR T-cell therapies for lymphoma, leukemia, and multiple myeloma
- A dedicated multidisciplinary CAR T-cell unit
- 24/7 monitoring capacity with ICU-level support
- Experienced specialists in hematology, immunotherapy, neurology, and infectious diseases
- International treatment protocols and international medical teams
We are committed to combining cutting-edge science with compassionate, individualized care—supporting patients and families at every step of the journey.
Frequently Asked Questions (FAQs)
Is CAR T-cell therapy right for me?
Eligibility depends on your diagnosis, prior treatments, overall health, and clinical evaluation. Our specialists provide a detailed assessment and personalized recommendation.
What are the long-term effects?
Patients may experience prolonged cytopenias or reduced antibody levels requiring ongoing monitoring. Long-term outcomes continue to be studied, and we provide structured follow-up care. Patients who have received CAR T-cell therapy are monitored closely over time, with regular follow-up care designed to detect and address any delayed complications that may occur. This careful observation helps ensure patient safety and supports the continued effectiveness of this innovative therapy.
How long does it take to feel the results?
Tumor response is typically assessed within the first month, though some patients continue improving over several months.
What can I expect during the CAR T-cell therapy process?
During the CAR T-cell therapy process, you will receive comprehensive care from a dedicated medical team that guides you through each step. The experience begins with an in-depth evaluation, where specialists discuss your treatment plan and answer any questions you may have. You then move to cell collection, a procedure called leukapheresis, with medical staff explaining the process to help you feel informed and comfortable. After your cells are engineered and infused back into your body, the team closely monitors your recovery, watching for side effects and offering ongoing support. Throughout every stage, all concerns are addressed and your well-being is the central focus, ensuring a smooth and reassuring experience.
Is CAR T-cell therapy painful?
The infusion itself is similar to a blood transfusion and is generally well tolerated.
How does CAR T-cell therapy compare to other cancer treatments?
CAR T-cell therapy differs from conventional cancer treatment methods like chemotherapy and radiation by providing a highly personalized and targeted approach. Chemotherapy and radiation typically attack rapidly dividing cells throughout the body, which can affect healthy tissue as well as cancer cells. In contrast, CAR T-cell therapy is a specialized form of immunotherapy that uses the patient’s own T-cells, genetically modified to seek out and destroy cancer cells. As a “living drug,” these modified immune cells continue working in the body to fight cancer over time. This patient-specific, biological treatment is designed to offer greater precision, and in some cases, more lasting effects compared to standard therapies.
Why choose Istanbul Florence Nightingale Hospital?
Istanbul Florence Nightingale Hospital, which is JCI accredited, stands out as a premier center for this advanced treatment, offering patients exceptional care and expertise. The hospital’s multidisciplinary and international team comprises experienced oncologists, hematologists, and immunologists who work collaboratively to develop and deliver treatment plans tailored to individual needs. The use of state-of-the-art medical technology and facilities ensures that each stage of the therapy, from cell collection to engineering, infusion, and post-treatment monitoring, is conducted with precision and safety. Istanbul Florence Nightingale Hospital’s unwavering commitment to personalized care is designed to optimize treatment results, support patient well-being, and achieve the best possible outcomes for those receiving advanced cancer therapy.
Ready to Learn More?
If you or a loved one has a relapsed or refractory blood cancer, our CAR T-cell team is here to help.
- Request a consultation
- Send your medical reports for evaluation
- Speak with one of our CAR T specialists
We are committed to providing every patient with individualized, world-class care and renewed hope for recovery.
